TEVA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: VTRS PRGO AMRX GSK BMY PFE MRK NVS ABBV JNJ

| Held by: IEFA EFA EFV EIS IXUS SPDW PPH FNDF IDEV WCMI

Index	-	P/E	39.80	EPS (ttm)	0.61	Insider Own	0.10%	Shs Outstand	1.15B	Perf Week	21.77%
Market Cap	27.97B	Forward P/E	8.70	EPS next Y	2.80	Insider Trans	-28.52%	Shs Float	1.15B	Perf Month	20.68%
Enterprise Value	42.85B	PEG	4.69	EPS next Q	0.67	Inst Own	63.21%	Short Float	4.13%	Perf Quarter	48.99%
Income	719.90M	P/S	1.66	EPS this Y	6.12%	Inst Trans	-1.48%	Short Ratio	4.41	Perf Half Y	34.98%
Sales	16.86B	P/B	4.10	EPS next Y	6.09%	ROA	1.76%	Short Interest	47.28M	Perf YTD	10.66%
Book/sh	5.95	P/C	12.70	EPS next 5Y	8.49%	ROE	10.78%	52W High	25.00 -2.44%	Perf Year	30.85%
Cash/sh	1.92	P/FCF	15.06	EPS past 3/5Y	- -9.62%	ROIC	2.96%	52W Low	12.47 95.67%	Perf 3Y	167.43%
Dividend Est.	-	EV/EBITDA	9.27	Sales past 3/5Y	1.38% -0.43%	Gross Margin	50.01%	Volatility	4.20% 3.01%	Perf 5Y	179.70%
Dividend TTM	-	EV/Sales	2.54	EPS Y/Y TTM	64.37%	Oper. Margin	21.37%	ATR (14)	0.85	Perf 10Y	-59.51%
Dividend Ex-Date	Nov 27, 2017	Quick Ratio	0.82	Sales Y/Y TTM	0.25%	Profit Margin	4.27%	RSI (14)	81.82	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.11	EPS Q/Q	196.37%	SMA20	20.64%	Beta	0.67	Target Price	29.29
Payout	-	Debt/Eq	2.35	Sales Q/Q	3.68%	SMA50	24.33%	Rel Volume	2.01	Prev Close	24.60
Employees	36167	LT Debt/Eq	2.35	Earnings	Nov 05 BMO	SMA200	40.88%	Avg Volume	10.73M	Price	24.39
IPO	Feb 16, 1982	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.03% 2.86%	Trades		Volume	19,050,959	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	Goldman	Buy	$24
May-28-25	Initiated	Truist	Buy	$25
May-12-25	Upgrade	JP Morgan	Neutral → Overweight	$23
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy	$10
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy	$10 → $13
Jun-14-22	Resumed	UBS	Neutral	$10
May-17-22	Upgrade	BofA Securities	Underperform → Neutral	$9

Show Previous Ratings

Today 11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
05:43AM	Teva (TEVA) Hits All-Time High as Q3 Strengthens FY25 Profitability Expectations (Insider Monkey)
Nov-05-25 05:53PM	Why Teva Pharmaceutical Stock Rocked the Market Today (Motley Fool) +20.23%
04:27PM	Teva Rockets, Reaffirming Its $2.5 Billion View For Austedo After IRA Negotiations (Investor's Business Daily)
04:21PM	Apple's reported Google deal, Teva & Axon post-earnings moves (Yahoo Finance Video)
02:00PM	Loading…
02:00PM	Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ... (GuruFocus.com)
12:58PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
11:05AM	Teva Rockets Into A Profit-Taking Zone On Austedo's Big Sales Beat (Investor's Business Daily)
09:30AM	Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings (Zacks)
08:49AM	Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike (Investor's Business Daily)
07:00AM	Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo and Non-GAAP EPS (GlobeNewswire)
Nov-04-25 09:15AM	Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Nov-03-25 08:00AM	Teva Kicks Off 'The Other TD' to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis (GlobeNewswire)
Oct-31-25 08:08PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
04:30PM	Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
03:08PM	Loading…
Oct-29-25 03:08PM	Trump Administration Eases Approval Process for Biosimilar Drugs (Barrons.com)
Oct-24-25 07:42AM	Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe (Insider Monkey)
Oct-22-25 03:45PM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Oct-21-25 12:00PM	All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy (Zacks)
09:55AM	Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect? (Zacks)
09:40AM	Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock? (Zacks)
09:13AM	Johnson & Johnson Targets Accelerated Growth Across Segments in 2026 (Zacks)
05:52AM	Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy (Insider Monkey)
Oct-20-25 11:07PM	JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA) (Insider Monkey)
04:30PM	Teva and Prestige Biopharma Enter License Agreement for Tuznue Commercialization in Europe (GlobeNewswire)
Oct-17-25 09:59AM	Teva Pharmaceutical Receives FDA Approval to Expand UZEDY Indication for Maintenance Treatment of Bipolar I Disorder (Insider Monkey)
Oct-16-25 09:40AM	Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock (Zacks)
Oct-14-25 12:00PM	JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit (Zacks)
Oct-13-25 10:15AM	TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder (Zacks)
08:44AM	BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid "Pivot to Growth" Strategy Execution (Insider Monkey)
04:10AM	Loading…
04:10AM	Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 (Motley Fool)
Oct-10-25 03:00PM	FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder (GlobeNewswire)
12:10PM	Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know (Zacks)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Oct-09-25 07:37AM	TSMC, SoftBank, HSBC, Ferrari: Stocks Worldwide in Focus (The Wall Street Journal)
07:37AM	SoftBank, HSBC, Teva, Ferrari: Stocks Worldwide in Focus (The Wall Street Journal)
05:10AM	Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials (The Wall Street Journal)
Oct-06-25 03:06AM	Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters (Motley Fool)
Oct-02-25 09:40AM	Can Galafold Drive Amicus' Growth Through the Rest of 2025? (Zacks)
Oct-01-25 08:38PM	UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00 (Insider Monkey)
08:11PM	Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA) (Insider Monkey)
Sep-30-25 09:40AM	Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term (Zacks) +5.32%
09:15AM	Here's How Alvotech is Expanding its Portfolio Beyond Immunology (Zacks)
Sep-25-25 04:30PM	Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 (GlobeNewswire)
04:30PM	Teva Releases Q3 2025 Aide Memoire (GlobeNewswire)
Sep-23-25 12:19PM	Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play? (Zacks)
Sep-22-25 02:19PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
09:16AM	J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock? (Zacks)
Sep-20-25 10:16PM	Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction (GlobeNewswire)
10:15PM	New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed (GlobeNewswire)
Sep-18-25 09:33AM	Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth (Zacks)
Sep-16-25 04:30PM	Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting (GlobeNewswire)
02:58PM	Teva Pharmaceutical Industries (TEVA) Attains FDA's Fast Track Designation for Emrusolmin (Insider Monkey)
09:26AM	Teva Pharmaceutical Industries Limited (TEVA)'s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy (Insider Monkey)
Sep-11-25 12:49PM	J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT (Insider Monkey)
Sep-10-25 10:18AM	Here's Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2 (Insider Monkey)
Sep-09-25 09:09AM	ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell? (Zacks)
08:30AM	Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy (GlobeNewswire)
Sep-04-25 10:30AM	TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock? (Zacks)
Sep-02-25 04:30PM	Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September (GlobeNewswire)
12:57PM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Aug-31-25 12:10AM	Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda (Insider Monkey)
Aug-29-25 05:02AM	Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY (Insider Monkey)
Aug-28-25 10:54AM	FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk (Investor's Business Daily)
08:30AM	Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) - First Generic GLP-1 Indicated for Weight Loss (GlobeNewswire)
Aug-25-25 11:29AM	Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA) (Insider Monkey)
08:39AM	J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy? (Zacks)
Aug-21-25 01:14PM	Latest Fed cut signals, pharma relief rally, Apple TV+ price hike (Yahoo Finance Video) +6.76%
11:32AM	US-EU trade deal impacts on pharma industry more 'manageable' than expected (Yahoo Finance)
09:18AM	Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds? (Zacks)
Aug-20-25 03:51AM	Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters (Motley Fool)
Aug-07-25 03:29PM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Aug-06-25 07:00AM	FDA Approves Expanded Indication for AJOVY (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine (GlobeNewswire)
Jul-31-25 12:38PM	TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales (Zacks) -8.20%
Jul-30-25 04:11PM	Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings (Investor's Business Daily)
01:15PM	Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy (Benzinga)
12:50PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
10:11AM	Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
09:30AM	Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics (Zacks)
07:00AM	Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components (GlobeNewswire)
Jul-29-25 12:00AM	Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics (Zacks)
Jul-25-25 11:28PM	Leader Capital Markets Remains Bullish on Teva Pharmaceutical Industries (TEVA) (Insider Monkey)
Jul-21-25 09:36AM	Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise? (Zacks)
Jul-18-25 12:40PM	Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1 (Bloomberg)
03:06AM	Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters (Motley Fool)
Jul-16-25 10:53AM	JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise (Zacks)
Jul-11-25 08:31AM	TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-09-25 12:55AM	Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278 (Insider Monkey)
Jul-08-25 05:32AM	Teva's Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial (Insider Monkey)
Jun-26-25 04:30PM	Teva Releases Q2 2025 Aide Memoire (GlobeNewswire)
11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-25-25 06:22PM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
04:30PM	Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 (GlobeNewswire)
08:44AM	Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys? (Motley Fool)
Jun-24-25 11:33AM	Teva reports final analysis of migraine prevention trial of Ajovy (Clinical Trials Arena)
04:25AM	Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth (Insider Monkey)
Jun-23-25 09:22AM	J&J Adds More Than $15B in Six Months: How to Play JNJ Stock? (Zacks)
03:00AM	Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic and Episodic Migraine (GlobeNewswire)
Jun-17-25 12:02PM	Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy (Zacks)
10:00AM	Generic Drugmakers Resist Trumps Calls for More U.S. Manufacturing (The Wall Street Journal)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bridger Management, LLC (1)	Shareholder	Sep 12 '25	Proposed Sale	19.89	95,000	1,889,550		Sep 12 04:05 PM
McAvoy David R.	EVP, Chief Legal Officer	Sep 05 '25	Buy	18.86	1,113	20,988	13,027	Sep 09 04:02 PM
Jover Placid	See "Remarks"	Aug 01 '25	Sale	15.16	6,053	91,748	6,774	Aug 05 04:04 PM
Hughes Eric A	See "Remarks"	Aug 01 '25	Sale	15.16	52,742	799,437	0	Aug 05 04:02 PM
Jover Placid	Officer	Aug 01 '25	Proposed Sale	15.16	6,053	91,748		Aug 01 04:04 PM
Hughes Eric A	Officer	Aug 01 '25	Proposed Sale	15.16	52,742	799,437		Aug 01 04:01 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Jun 12 '25	Sale	17.08	55,775	952,464	403,288	Jun 16 04:03 PM
Kalif Eliyahu Sharon	Officer	Jun 12 '25	Proposed Sale	17.08	55,775	952,466		Jun 12 04:18 PM
Shields Matthew	EVP, Global Operations	Jun 03 '25	Sale	17.02	6,206	105,628	9,989	Jun 05 05:08 PM
Shields Matthew	Officer	Jun 03 '25	Proposed Sale	17.02	6,206	105,628		Jun 03 03:59 PM
Sabag Mark	See "Remarks"	May 08 '25	Sale	18.04	337,915	6,097,304	150,996	May 12 04:00 PM
Sabag Mark	Officer	May 08 '25	Proposed Sale	18.04	337,915	6,097,324		May 08 02:34 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	70,961	1,128,642	48,384	Mar 07 04:05 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.73	15,174	238,757	8,077	Mar 06 04:11 PM
Hughes Eric A	See "Remarks"	Mar 05 '25	Sale	15.91	8,077	128,531	0	Mar 06 04:11 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.73	91,608	1,441,415	7,108	Mar 06 04:06 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	48,764	775,991	0	Mar 06 04:06 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.73	15,514	244,107	280,042	Mar 06 04:03 PM
Francis Richard D	President and CEO	Mar 05 '25	Sale	15.91	8,259	131,427	271,783	Mar 06 04:03 PM
Daniell Richard	Officer	Mar 05 '25	Proposed Sale	15.83	70,961	1,123,585		Mar 05 04:29 PM
Daniell Richard	Exec. VP, European Commercial	Mar 03 '25	Sale	16.19	49,314	798,172	12,936	Mar 05 04:12 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.56	12,936	201,253	0	Mar 05 04:12 PM
Hughes Eric A	See "Remarks"	Mar 03 '25	Sale	16.19	19,726	319,275	5,174	Mar 05 04:08 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.56	5,174	80,495	0	Mar 05 04:08 PM
Francis Richard D	President and CEO	Mar 03 '25	Sale	16.19	24,892	402,889	251,783	Mar 05 04:04 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.56	6,450	100,347	245,333	Mar 05 04:04 PM
Fox Christine	Officer	Mar 04 '25	Proposed Sale	16.00	6,181	98,896		Mar 04 07:02 PM
McAvoy David R.	Officer	Mar 04 '25	Proposed Sale	16.00	4,827	77,232		Mar 04 06:57 PM
Hughes Eric A	Officer	Mar 04 '25	Proposed Sale	16.00	23,251	372,016		Mar 04 06:44 PM
Daniell Richard	Officer	Mar 04 '25	Proposed Sale	16.00	86,400	1,382,400		Mar 04 06:37 PM
Francis Richard D	Officer	Mar 04 '25	Proposed Sale	16.00	23,773	380,368		Mar 04 06:30 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Feb 28 '25	Sale	16.21	55,750	903,462	147,941	Mar 04 04:02 PM
Francis Richard D	Officer	Mar 03 '25	Proposed Sale	16.46	31,342	515,889		Mar 03 01:14 PM
Hughes Eric A	Officer	Mar 03 '25	Proposed Sale	16.46	24,900	409,854		Mar 03 01:07 PM
Daniell Richard	Officer	Mar 03 '25	Proposed Sale	16.46	62,250	1,024,635		Mar 03 12:59 PM
Kalif Eliyahu Sharon	Officer	Feb 28 '25	Proposed Sale	16.21	55,750	903,463		Feb 28 11:52 AM
Francis Richard D	President and CEO	Feb 18 '25	Sale	16.95	75,506	1,279,661	209,444	Feb 19 04:03 PM
Francis Richard D	Officer	Feb 18 '25	Proposed Sale	16.95	75,506	1,279,661		Feb 18 12:38 PM
Sabag Mark	See "Remarks"	Feb 12 '25	Sale	16.25	177,626	2,886,565	204,964	Feb 14 04:03 PM
Sabag Mark	Officer	Feb 12 '25	Proposed Sale	16.25	177,626	2,886,555		Feb 13 08:06 AM
MIGNONE ROBERTO	Director	Dec 20 '24	Sale	22.01	286,000	6,294,031	695,000	Dec 26 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 20 '24	Proposed Sale	21.31	286,000	6,094,660		Dec 20 07:03 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '24	Sale	16.87	19,388	327,085	44,104	Nov 21 04:04 PM
Fox Christine	Officer	Nov 20 '24	Proposed Sale	16.87	19,388	327,085		Nov 20 11:39 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd. ADR

Upgrade your FINVIZ experience